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A sensitive and simultaneous liquid chromatography–tandem mass spectrometry method was developed
and validated for quantiﬁcation of ethinyl estradiol and levonorgestrel. The analytes were extracted with
methyl-tert-butyl ether: n-hexane (50:50, v/v) solvent mixture, followed by dansyl derivatization. The
chromatographic separation was performed on a Kinetex C18 (50 mm4.6 mm, 2.6 mm) column with a
mobile phase of 0.1% (v/v) formic acid in water and acetonitrile in gradient composition. The mass
transitions were monitored in electrospray positive ionization mode. The assay exhibited a linear range
of 0.100–20.0 ng/mL for levonorgestrel and 4.00–500 pg/mL for ethinyl estradiol in human plasma. A run
time of 9.0 min for each sample made it possible to analyze a throughput of more than 100 samples per
day. The validated method has been successfully used to analyze human plasma samples for application
in pharmacokinetic and bioequivalence studies.
& 2015 Xi'an Jiaotong University. Production and hosting by Elsevier B.V. All rights reserved. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Levonorgestrel/ethinyl estradiol is a progesterone and estrogen
combination birth control pill. It works by preventing ovulation,
thickening the mucus in the cervix and changing the lining of the
uterus [1]. Combination oral contraceptives act by suppression of
gonadotropins [2].
Levonorgestrel is rapidly and completely absorbed after oral ad-
ministration (bioavailability about 100%). It is not subjected to ﬁrst-
pass metabolism or enterohepatic circulation. Therefore, it does not
undergo variations in absorption after oral administration. Ethinyl
estradiol is rapidly and almost completely absorbed by the gastro-
intestinal tract, but due to ﬁrst-pass metabolism in gut mucosa and
liver, the bioavailability of ethinyl estradiol is within 38%–48% [2].
The kinetics of total levonorgestrel is non-linear due to an in-
crease in binding of levonorgestrel to sex hormone binding glo-
bulin (SHBG), which is attributed to increased SHBG level that is
induced by the daily administration of ethinyl estradiol [2]. Levo-
norgestrel in serum is primarily bound to SHBG. Ethinyl estradiol
is about 97% bound to plasma albumin. Ethinyl estradiol does not
bind to SHBG, but induces SHBG synthesis.on and hosting by Elsevier B.V. All
University.
: þ91 79 30013010.
edi).The most important metabolic pathway of levonorgestrel oc-
curs in the reduction of the D 4-3-oxo group and hydroxylation at
positions 2a, 1b, and 16b, followed by conjugation. Most of the
metabolites that circulate in the blood are sulfates of 3a, 5b-tet-
rahydro-levonorgestrel, while excretion occurs predominantly in
the form of glucuronides. Some of the parent levonorgestrel also
circulates as 17b-sulfate [2].
Cytochrome P450 enzymes (CYP3A4) in the liver are re-
sponsible for the 2-hydroxylation of ethinyl estradiol, the major
oxidative reaction. The 2-hydroxy metabolite is further trans-
formed by methylation and glucuronidation prior to urinary and
fecal excretion. Levels of cytochrome P450 (CYP3A) vary widely
among individuals and can explain the variation in rates of ethinyl
estradiol 2-hydroxylation. Ethinyl estradiol is excreted into the
urine and feces as glucuronide and sulfate conjugates, and un-
dergoes enterohepatic circulation [2].
Evaluation of bioequivalence requires pharmacokinetic plotting
of time–concentration proﬁle to be accurate. A method for si-
multaneous extraction is required to extract analyte of interest
selectively without co-extracting conjugated metabolites of these
drugs which may be back-converted to the parent drug during the
derivatization procedure.
A few assays have been reported for individual analysis of
ethinyl estradiol and levonorgestrel in human plasma. However,
they either lack the sensitivity required especially for ethinylrights reserved. This is an open access article under the CC BY-NC-ND license
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ments of the proposed work [3–14]. Matějíček and Kubáň [5] re-
ported a method for simultaneous analysis; however, the method
was not optimized for estimation of ethinyl estradiol and levo-
norgestrel in human plasma samples. In another report, a semi-
automated method for the simultaneous determination of oral
contraceptives concentration in human plasma was reported with
shorter run time [10]. However, the method lacked the required
sensitivity level as the lower limit of quantiﬁcation (LLOQ) for
ethinyl estradiol was 10 pg/mL, which was almost 10% of the re-
ported Cmax.
The method presented has the highest extensive range of lin-
earity 4.00–500 pg/mL (125 times) and 0.100–20.0 ng/mL (200
times) compared with the reported methods for ethinyl estradiol
and levonorgestrel in human plasma. The plasma volume for
sample preparation was 500 mL, which was considerably less than
or similar to that in other reported methods [3–4]. The on-column
loading of ethinyl estradiol and levonorgestrel at LLOQ was only
300 fg and 7.5 pg per sample injection volume respectively, which
was signiﬁcantly lower than that in all other reported procedures
[3–14]. The proposed method was validated and its application to
sample analysis was performed using the Watson LIMS software,
which provided excellent data integrity, and they are essential
requirements of current regulatory bodies. None of the methods
and application were presented with the same. The results and
discussion of the incurred sample reanalysis (ISR), which were
obtained after implementing the proposed method, have not been
discussed or presented in any of the reported methods [3–5].2. Experimental
2.1. Chemicals and materials
Reference standards of ethinyl estradiol (Lot No.: Q0162;
100.0% purity) and levonorgestrel (Lot No.: F0H323; 99.3% purity)
were obtained from USP (Rockville, USA). Ethinyl estradiol-D4
(97.1% purity) and levonorgestrel-D6 (99.9% purity) as internal
standard (IS) were obtained from Clearsynth Labs Limited
(Mumbai, India) and TLC Pharmachem Inc. (Concord, Canada),
respectively. Dansyl chloride was obtained from Sigma Aldrich
(Bengaluru, India). Sodium bicarbonate and sodium hydroxide of
GR grade were procured from S.d. Fine Chem Private Limited
(Mumbai, India). Formic acid and ammonia solution of GR grade
were procured from Merck Private Limited (Mumbai, India). HPLC
grade methyl-tert-butyl ether, acetone, acetonitrile and methanol
were procured from J.T. Baker Private Limited (Mumbai, India).
Water used in the entire analysis was prepared by the Milli-Q
water puriﬁcation system from Millipore (Bengaluru, India). BlankFig. 1. Product ion mass spectra of levonorgestrel (m/z 313.3-245human plasma with sodium heparin as an anticoagulant was ob-
tained from clinical laboratory Supratech Micropath (Ahmedabad,
India). Blank plasma was stored at –20 °C until use.
2.2. Liquid chromatography and mass spectrometric conditions
A UFLC XR prominence system (Kyoto, Japan) consisting of an
LC-20AD XR prominence pump, an SIL-20AC XR prominence auto-
sampler, a CTO-20AC XR prominence column oven and a DGU-20A3
prominence degasser was used for setting the reverse-phase liquid
chromatographic conditions. The separation of both analytes and
respective internal standard (IS) was performed on a Phenomenex
analytical column, type Kinetex C18 (50 mm4.6 mm, 2.6 mm).
Column temperature was maintained at 30 °C in column oven. The
mobile phase consisted of 0.1% (v/v) formic acid in water:acetoni-
trile with gradient elution from 60% to 90% of acetonitrile compo-
sition over a run time of 9.0 min. For gradient elution, the ﬂow rate
of the mobile phase was kept at 0.7 mL/min. The total chromato-
graphic run time was 9.0 min. The autosampler temperature was
maintained at 5 °C, and the pressure of the system was in the vi-
cinity of 2000 psi.
Ionization and detection of analytes and IS were carried out on a
triple quadrupole mass spectrometer, AB SCIEX API-5500 (Toronto,
Canada), equipped with electrospray ionization (TIS interface of the
API 5500) and operated in the positive ion mode. Quantitation was
performed using multiple reaction monitoring (MRM) mode to
monitor parent-product ion (m/z) transitions 313.3-245.3 for
levonorgestrel (Fig. 1) and 319.3-251.3 for levonorgestrel-D6 as an
IS (ﬁgure not shown). Ethinyl estradiol and ethinyl estradiol-D4 as
an IS were quantitatively derivatized with dansyl chloride. The mass
transitions for both compounds were 530.1-171.0 (Fig. 2) and
534.1-171.0 (ﬁgure not shown), respectively. The source depen-
dent parameters maintained for all analytes were Gas 1 (Nebulizer
gas): 40.0 psig; Gas 2 (heater gas ﬂow): 60.0 psig; ion spray voltage
(ISV): 5000.0 V, turbo heater temperature (TEM): 550.0 °C; interface
heater (Ihe): ON; entrance potential (EP): 10.0 V; collisional acti-
vated dissociation (CAD): 8 psig; and curtain gas (CUR), nitrogen:
30 psig. Compound speciﬁc values of mass spectrometer para-
meters are listed in Table 1. Analyst software version 1.6.2 was used
to control all parameters of liquid chromatography (LC) and mass
spectrometry (MS). WATSON LIMS software version 7.3 was used
for regression and ﬁnal data processing.
2.3. Standard stock, calibration standards and quality control sample
preparation
The standard stock solutions of ethinyl estradiol (0.1 mg/mL)
and levonorgestrel (1 mg/mL) were prepared by dissolving re-
quisite amount of them in methanol. Calibration standards and.3, scan range 100–350 amu) in the positive ionization mode.
Fig. 2. Product ion mass spectra of dansyl chloride derivatized ethinyl estradiol (m/z 530.1-171.0, scan range 100–540 amu) in the positive ionization mode.
Table 1
Values of compound speciﬁc mass spectrometer parameters.
Parameters Ethinyl estradiol Ethinyl estradiol-D4 Levonorgestrel Levonorgestrel-D6
Mass transitions (m/z) 530.1-171.0 534.1-171.0 313.3-245.3 319.3-251.3
Declustering potential (V) 70 70 150 150
Collision energy (V) 50 50 25 25
Collision cell exit potential (V) 15 15 12 12
Dwell time (ms) 200 50 200 50
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plasma volume) blank plasma with serially diluted spiking solu-
tions. Calibration curve standards were made at 4.00, 8.00, 15.0,
30.0, 60.0, 120, 250 and 500 pg/mL for ethinyl estradiol and 0.100,
0.200, 0.500, 1.00, 2.00, 5.00, 10.0 and 20.0 ng/mL for levonorgestrel,
respectively, while QC samples were prepared at ﬁve concentration
levels, viz. 400 pg/mL (high quality control (HQC)), 200/48.0 pg/mL
(medium quality control (MQC1/2)), 12.0 pg/mL (low quality control
(LQC)) and 4.00 pg/mL (LLOQ QC) for ethinyl estradiol. The QC
concentrations of 16.0, 8.00, 1.50, 0.300 and 0.100 ng/mL were ap-
plied for levonorgestrel. Stock solutions of ethinyl estradiol-D4
(0.100 mg/mL) and levonorgestrel-D6 (1.00 mg/mL) were prepared
by dissolving 2.0 mg each of them in appropriate volumes of me-
thanol. Mixed working IS solution containing 5.0 ng/mL ethinyl
estradiol-D4 and 80.0 ng/mL levonorgestrel-D6 was prepared by
appropriate dilution of the stock solution in methanol. All the so-
lutions (standard stock, calibration standards and quality control
samples) were stored at 2–8 °C until use.
2.4. Sample extraction protocols
Prior to analysis, all frozen subject samples, calibration stan-
dards and QC samples were thawed and allowed to equilibrate at
room temperature.
To an aliquot of 500 mL of spiked plasma sample, 50 mL of mixed
IS solution and 500 mL of 2% (v/v) ammonia solution in acetonitrile
were added and vortex mixed for 1 min to precipitate the plasma
proteins. Extraction of analytes and IS was done in 2.0 mL of me-
thyl-tert-butyl ether: n-hexane (50:50, v/v) solvent mixture on a
rotary mixer (rotospin) for 10 min at 32g. Samples were cen-
trifuged at 3208g for 5 min at 10 °C. The organic layer (2.0 mL) was
separated and evaporated to dryness in a thermostatically con-
trolled water bath maintained at 55 °C under a gentle stream of
nitrogen. The dried samples were derivatized with 200 mL of so-
dium bicarbonate solution (pH 11.0, 50 mM) and 200 mL of dansyl
chloride solution (1 mg/mL) in acetone by incubating the samples
for 10 min in water bath maintained at a temperature of 55 °C.
After incubation completion, the samples were again subjected toliquid–liquid extraction (LLE) to separate out dansylinic acid waste
product during the derivatization process. 2.5 mL of n-heptane
was added to all the samples. The samples were extracted on a
rotary mixer for 10 min at 32g and centrifuged at 3208g for 5 min
at 10 °C. The organic layer (2.0 mL) was separated and evaporated
to dryness in a thermostatically controlled water-bath maintained
at 55 °C under a gentle stream of nitrogen. The dried samples were
reconstituted with 100 mL of mobile phase, vortexed to mix for
10 s, and 15 mL was injected into the chromatographic system.
2.5. Method validation procedures
The bioanalytical method was fully validated following the
United States Food and Drug Administration (USFDA) guidelines
[15]. System suitability experiment was performed by six con-
secutive injections using the aqueous standard mixture of both
analytes and their IS at the start of each batch during method
validation. System performance was studied by injecting one ex-
tracted blank (without analyte and IS) and one ULOQ (the upper
limit of quantiﬁcation) sample and one LLOQ sample with re-
spective IS at the beginning of each analytical batch and before re-
injecting any sample during method validation. Carryover effect of
autosampler was checked to verify any carryover of the analyte at
the start and at the end of each batch. The design of the experi-
ment comprised the following sequence of injections viz. extracted
blank sample-ULOQ sample-two extracted blank samples-
LLOQ sample.
Selectivity of the method towards endogenous plasma matrix
components was assessed in nine different batches of plasma, of
which seven were normal sodium heparin plasma and one each of
lipidemic and haemolyzed plasma. Selectivity of the method to-
wards commonly used medications in human volunteers was
evaluated for acetaminophen, cetirizine, domperidone, ranitidine,
diclofenac, ibuprofen, nicotine and caffeine in six different batches
of human plasma containing sodium heparin as the anticoagulant.
Linearity of the method was determined by analysis of three
linearity curves containing eight non-zero concentrations. Area
ratio responses for ethinyl estradiol/ethinyl estradiol-D4 and
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monitoring were used for regression analysis. Each calibration
curve was analyzed individually using least square weighted (1/x2)
linear regression which was ﬁnalized during pre-method valida-
tion. A correlation coefﬁcient (r2) value of greater than 0.99 was
desirable for all the calibration curves. The lowest standard on the
calibration curve was accepted as LLOQ, if the analyte response
was at least ﬁve times more than that of drug-free (blank) ex-
tracted plasma. In addition, the analyte peak of the LLOQ sample
should be identiﬁable, discrete and reproducible with a precision
(%CV) less than 20% and accuracy within 80%–120%. Deviation of
the standards other than LLOQ from nominal concentration should
not be more than 715%.
For determining intra-batch accuracy and precision, replicate
analyses of plasma samples were performed on the same day. The
run consisted of a calibration curve and six replicates of LLOQ QC,
LQC, MQC2, MQC1 and HQC samples. Inter-batch accuracy and
precision were assessed by analyzing ﬁve precision and accuracy
batches on three consecutive validation days. Precision at each
concentration level from the nominal concentration should not be
greater than 15%. Similarly, the mean accuracy should be within
85%–115%, except for the LLOQ QC where it should be from 80% to
120% of the nominal concentration. Ion suppression/enhancement
effects on the multiple reaction monitoring liquid chromato-
graphy-tandem mass spectrometry (MRM LC–MS/MS) sensitivity
were evaluated by the post-column analyte infusion experiment.
Standard solution containing ethinyl estradiol, levonorgestrel (at
ULOQ level) and both IS was infused into the post column via a ‘T’
connector into the mobile phase at 10 mL/min employing infusion
pump. Aliquots of 15 mL of extracted control plasma were then
injected into the column by the autosampler. Any dip in the
baseline upon injection of double blank plasma (without IS) would
indicate ion suppression, while a peak at the retention time of
analyte or IS indicated ion enhancement.
Relative recovery (RE), absolute matrix effect (ME) and process
efﬁciency (PE) were assessed. All three parameters were evaluated
at HQC, MQC1, MQC2 and LQC levels in six replicates. RE was
calculated by comparing the mean peak area response of extracted
samples (spiked before extraction) with that of unextracted sam-
ples (spiked after extraction) at each QC level. Recovery of IS was
estimated in the similar way. ME was assessed by comparing the
mean peak area response of unextracted samples (spiked after
extraction) with mean peak area of neat standard solutions.
Overall PE was calculated as (MERE)/100%.
All stability results were evaluated by measuring the area ratio
response (drug/IS) of stability samples against freshly prepared
comparison standards with identical concentration. Stock solu-
tions of analytes and IS were checked for short-term stability at
room temperature and long-term stability at 5 °C. The solutions
were considered stable if the deviation from nominal value was
within 710.0%. Autosampler stability (extract stability at 2–8 °C
and at ambient temperature), bench-top (at room temperature)
and freeze–thaw (ﬁve cycles) stability experiments were per-
formed at LQC and HQC levels using six replicates. Freeze–thaw
stability was evaluated by successive cycles of freezing (at 20
and 70 °C) and thawing (without warming) at room tempera-
ture. Long-term stability of spiked plasma samples stored at 20
and 70 °C was also studied at both levels. The samples were
considered stable if the deviation from the mean calculated con-
centration of freshly thawed QC samples was within 715.0%.
To authenticate ruggedness of the proposed method, it was
performed with two precision and accuracy batches. The ﬁrst
batch was analyzed by different analysts, while the second batch
was studied on two different columns. Dilution integrity experi-
ment was evaluated by spiking the QC sample at 800 pg/mL
ethinyl estradiol and 32.0 ng/mL levonorgestrel concentration inthe screened plasma. The precision and accuracy for dilution in-
tegrity standards at 1/10th dilution were determined by analyzing
the samples against calibration curve standards.
2.6. Bioequivalence study design and incurred sample reanalysis
Design of the study comprised a randomized, open label, two
treatment, two period, two sequence, single dose, crossover
bioequivalence study of levonorgestrel/ethinyl estradiol tablets
0.15 mg/0.03 mg (two tablets as a single dose) of test formulation
and Microgynon
s
30 ED (levonorgestrel/ethinyl estradiol tablets
0.15 mg/0.03 mg) tablets (two tablets as a single dose) of Bayer
Australia Limited in healthy, adult, female, human subjects under
fasting conditions. Each subject was judged to be in good health
through medical history, physical examination and routine la-
boratory tests. Written consent was taken from all the subjects
after informing them about the objectives and possible risks in-
volved in the study. An independent ethics committee constituted
as per Indian Council of Medical Research (ICMR) approved the
study protocol. The study was conducted strictly in accordance
with guidelines laid down by the International Conference on
Harmonization and USFDA. The subjects were fasted 10 h before
administration of the drug formulation. They were orally ad-
ministered a single dose of test and reference formulations after a
recommended wash out period of 28 days with 240 mL of water.
Blood samples were collected at the pre-dose, 0.33, 0.67, 1.00, 1.25,
1.50, 1.75, 2.00, 2.33, 2.67, 3.00, 3.50, 4.00, 6.00, 8.00, 11.00, 15.00,
18.00, 24.00, 36.00, 48.00, 60.00 and 72.00 h after oral adminis-
tration of the dose for test and reference formulations in labeled
sodium heparin vacutainer. The maximum volume of blood
withdrawn during the entire study was not more than 362 mL,
which included 322 mL for pharmacokinetic analysis, 10 mL for
screening, 10 mL for post-study safety assessment (hematology
and biochemical tests), while a total of 20 mL of heparinized blood
was discarded prior to sampling through the venous cannula for
each subject in both the periods. Plasma was separated by cen-
trifugation and kept frozen at 20 °C until completion of the
period and then at 70 °C until analysis. During the study, sub-
jects had a standard diet, while water intake was unmonitored. An
incurred sample re-analysis (assay reproducibility test) was also
conducted by computerized random selection of subject samples.
10% of the total samples were re-analyzed for incurred sample
reanalysis experiment. The selection criteria included minimum
two samples per period, which were close to the Cmax and the
elimination phase in the pharmacokinetic proﬁle of the drugs. The
results obtained were compared with the data obtained earlier for
the same sample using the same procedure. The percentage
change in the value should not be more than 720%.
Change %
Repeat value Initial value
Mean of repeat and initial values
100%( ) = – ×
2.7. Statistical analysis
The pharmacokinetic parameters of ethinyl estradiol and le-
vonorgestrel were estimated by a non-compartmental model
using WinNonlin software version 5.2.1 (Pharsight Corporation,
Sunnyvale, CA, USA). The Cmax values and the time to reach max-
imum plasma concentration (tmax) were estimated directly from
the observed plasma concentration vs. time data. The area under
the plasma concentration–time curve from time 0 to 72 h (AUC0–
72) was calculated using the linear trapezoidal rule. The AUC0-inf
was calculated as: AUC0-inf¼AUC0–72þCt/Kel, where Ct is the last
plasma concentration measured and Kel is the elimination rate
constant; Kel was determined using linear regression analysis of
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The t1/2 was calculated as: t1/2¼ ln 2/Kel. To determine whether the
test and reference formulations were pharmacokinetically
equivalent, Cmax, AUC0–72, AUC0-inf and their ratios (test/reference)
using log transformed data were assessed. Their means and 90%
conﬁdence intervals (CIs) were analyzed using SAS
s
software
version 9.1.3 (SAS Institute Inc., Cary, NC, USA). The drugs were
considered pharmacokinetically equivalent if the difference be-
tween the compared parameters was statistically non-signiﬁcant
(PZ0.05), and the 90% CIs for these parameters fell within
80%–125%.3. Results and discussion
3.1. Method development
To develop a selective, rugged and reliable method for the si-
multaneous estimation of ethinyl estradiol and levonorgestrel in
human plasma, the three commonly used extraction procedures
were systematically investigated. The chromatographic and mass
spectrometric conditions were suitably optimized to get the de-
sired sensitivity, selectivity and linearity in regression curves.
3.1.1. Mass spectrometry
Levonorgestrel and ethinyl estradiol were tuned in atmospheric
pressure chemical ionization (APCI) mode considering its nonpolar
steroidal moiety. Though levonorgestrel produced a high intense
signal in APCI mode and ethinyl estradiol in derivatized or under-
ivatized form did not produce the required signal in APCI mode, the
electrospray ionization (ESI) mode with positive polarity was used,
which provided a good signal for both analytes. The dansyl deriva-
tization of ethinyl estradiol introduced basic secondary nitrogen into
the molecule that was readily ionized in acidic HPLC mobile phases.
The derivative showed an intense protonated molecular ion at m/z
530.1 under positive turbo ion spray ionization. The collision-induced
dissociation of this ion formed a distinctive product ion at m/z 171.0,
corresponding to the protonated 5-(dimethylamino) naphthalene
moiety. The selected reaction monitoring, based on the m/z 530.1-
171.0 transition, was used for ethinyl estradiol. This allowed for an
LLOQ of 4.00 pg/mL for ethinyl estradiol and 0.100 ng/mL for levo-
norgestrel using a 500 μL plasma sample and injecting 15 μL of
dansylated derivative into the Shimadzu UFLC XR prominence auto-
sampler coupled to an AB Sciex API 5500 triple quadrupole mass
spectrometer. Though dansyl chloride also reacted with amines in
the samples, the selected reaction monitoring, based on the m/z
530.1-171.0 transition, was made speciﬁc for ethinyl estradiol by
separating the analyte of interest peak chromatographically using
gradient elution pattern and ultimately eliminating the background
noise observed at retention time from blank plasma. Initially, the
precursor and product ions were optimized by infusing 200 ng/mL
solutions in the mass spectrometer between m/z 100 and 550. Q1
MS full scan spectra for ethinyl estradiol and its IS predominantly
contained protonated precursor [MþH]þ ions atm/z 530.1 and 534.1
of their dansylated derivatives, respectively. The most abundant and
consistent common product ions in Q3 MS spectra for ethinyl es-
tradiol and its IS were observed at m/z 171.0 by applying collision
energy of 50 eV. The source dependent and compound dependent
parameters were suitably optimized to obtain a consistent and
adequate response to the analyte. A dwell time of 200 ms for the
drug and 50 ms for its IS was adequate and no cross talk was ob-
served between their MRMs.
3.1.2. Optimization of extraction technique
Reported procedures for the estimation of ethinyl estradiol in
human plasma have used either LLE or solid phase extraction forsample preparation with little or no information on ion suppres-
sion or matrix interference. Considering the steroidal moiety in
chemical structures of both analytes and the high log P value,
protein precipitation followed by LLE was tried by using the var-
ious combinations of organic solvents like diethyl ether, ethyl
acetate, methyl tert-butyl ether, n-hexane and n-heptane. The
samples were precipitated with the equal amount of acetonitrile to
plasma, and LLE with methyl tert-butyl ether combined with
n-hexane in a proportion of 50:50 (v/v) gave good response and
desired recovery through the extraction. After selective extraction
of both analytes, the organic supernatant layer was separated and
evaporated to dryness. The dried residue was subjected to dansyl
derivatization in alkaline pH at an incubation temperature of 55 °C
for 10 min. After derivatization, to protect the silica-based column
from exposing to high alkaline pH incorporated during the deri-
vatization procedure, the derivatives were re-extracted in organic
solvent with n-heptane. To reconstitute the ﬁnal product, various
combinations of ammonium acetate, formic acid or ammonium
formate solutions with acetonitrile were tried. The samples were
reconstituted with initial mobile phase composition as 0.1% (v/v)
formic acid in water:acetonitrile (40:60, v/v), which provided
help to improve the sensitivity, compatibility and reproducible
response.
3.1.3. Optimization of chromatographic conditions
To have a rugged and efﬁcient chromatography, efforts were
made to minimize matrix interference, achieve adequate run time in
order to ensure high throughput and attain high sensitivity with
good peak shapes. The analytical potential of four different reversed-
phase columns was evaluated, namely, Atlantis C18 (100 mm
2.1 mm, 3 mm), Kinetex C18 (50 mm4.6 mm, 2.6 mm), Kinetex PFP
(50 mm4.6 mm, 2.6 mm) and Kinetex C18 (50 mm2.1 mm,
2.6 mm) analytical columns. Separation was tried using various
combinations of methanol/acetonitrile in acidic buffer (2–20 mM
ammonium formate) and additives like formic acid (0.01–0.1%) on
these columns to ﬁnd the optimal mobile phase that produced the
best sensitivity, efﬁciency and peak shape. Levonorgestrel required a
relatively higher portion of aqueous composition to separate closely
eluting interferences on selected MRM, while derivatized ethinyl
estradiol required a higher portion of organic composition to elute
out in relatively shorter retention time while still maintaining the
selectivity. The required sensitivity and selectivity at femtogram level
on the columnwere adversely affected by high background noise and
many similar MRM transition peaks for ethinyl estradiol. Further-
more, it was required to wash out the retained interferences in the
column after elution of the analyte. Hence, careful optimization of
chromatography was needed with gradient programming starting
from lower organic portion (60%) till separation of levonorgestrel
peak to 70% organic portion till separation of ethinyl estradiol and
providing nonpolar interference wash out with 90% of organic pro-
portion. In the present work, the best chromatographic conditions as
a function of analyte peak intensity, peak shape, adequate retention
and analysis run time were achieved with Kinetex C18
(50 mm4.6 mm, 2.6 mm) using 0.01% (v/v) formic acid in water:
acetonitrile (40:60 to 10:90 (v/v) gradient programming) as the
mobile phase. The total chromatographic run time was 9.0 min with
a retention time of 1.6 and 5.8 min for levonorgestrel and ethinyl
estradiol, respectively. The sensitivity achieved for ethinyl estradiol
and levonorgestrel was 4.00 pg/mL and 0.100 ng/mL, respectively,
which was greater compared with other methods reported in human
plasma. Based on the selectivity (unperturbed and stable base line)
and signal-to-noise ratio (S/NZ19), it was possible to further lower
the LLOQ by about two folds; however, it was not required based on
the results of subject samples. Representative MRM ion chromato-
grams of extracted blank human plasma (double blank) at LLOQ for
ethinyl estradiol (Fig. 3) and levonorgestrel (Fig. 4) demonstrated the
Fig. 3. MRM ion-chromatograms of (A) double blank plasma (without IS), (B) ethinyl estradiol at LLOQ (m/z 530.1-171.0) 4.00 pg/mL and IS, and (C) subject sample at
12.6 pg/mL concentration.
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peak shape for both the drugs.
Ethinyl estradiol-D4 and levonorgestrel-D6 were the deuterated
compounds selected as internal standards in the present work. They
had similar chromatographic behavior and were easily separated
and eluted along with the analytes. There was no effect of IS on
analyte recovery, sensitivity or ion suppression. Optimized method
was evaluated for interference by the presence of lysophospholipid
as shown in Fig. 5 and post-column ionization impact as shown in
Fig. 6. The method was found successfully separating the inter-
ferences causing any ionization impact.3.2. Assay performance and validation
Throughout the method validation, the precision (%CV) of the
system suitability test was observed r3.88% for analyte retention
time (RT), IS RT and area ratio of analytes and respective IS, while
the signal-to-noise ratio for system performance was Z19.5 and
Z92.4 for ethinyl estradiol and levonorgestrel, respectively. Car-
ryover evaluation was performed in each analytical run so as to
ensure that it did not affect the accuracy and the precision of the
proposed method. No enhancement in the response was observed
in the double blank (without analyte and IS) after subsequent in-
jection of the highest calibration standard (aqueous and extracted)
at the retention time of the analyte and respective IS.
Fig. 4. MRM ion-chromatograms of (A) double blank plasma (without IS), (B) levonorgestrel at LLOQ (m/z 313.3-245.3) 0.100 ng/mL and IS, and (C) subject sample at
0.593 ng/mL concentration.
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range of 4.00–500 pg/mL for ethinyl estradiol and 0.100–
20.0 ng/mL for levonorgestrel. A straight-line ﬁt was made
through the data points by the least square regression analysis,
and a constant proportionality was observed. The regression was
performed using the Watson LIMS (Laboratory Information Man-
agement System) software, version 7.3 to get the high throughput
and highest integrity of data without human intervention. The
calibration curve (ﬁtted by ﬁrst order y¼axþb, where a is the
slope, b is the intercept, x is the concentration and y is the peak
area ratio of drug to IS) was plotted as the peak area ratio (drug to
IS) on Y-axis vs. the nominal concentration of the drug on X-axis.
The accuracy and precision (%CV) for the calibration curve
standards were found within 715.0% for both drugs. The lowest
concentration (LLOQ) in the standard curve that could bemeasured with acceptable accuracy and precision was found to be
4.00 pg/mL for ethinyl estradiol and 0.100 ng/mL for levonorges-
trel in plasma at a signal-to-noise ratio (S/N) of Z19.5 and Z92.4,
respectively.
The intra-batch and inter-batch precision and accuracy were
established from validation runs performed at HQC, MQC1, MQC2,
LQC and LLOQ QC levels (Table 2).
The relative recovery and matrix factor data for ethinyl estra-
diol and IS are presented in Table 3. The relative recovery of the
analyte was the ‘true recovery’, which was unaffected by the
matrix as it was calculated by comparing the peak area ratio re-
sponse (analyte/IS) of the extracted (spiked before extraction) and
unextracted (spiked after extraction) samples. The relative re-
covery was Z94.06% for ethinyl estradiol and its IS and Z94.78%
for levonorgestrel and its IS. Recovery was consistent across all QC
Fig. 5. Chromatographic separation of ethinyl estradiol and levonorgestrel from retention time of lysophospholipid.
Fig. 6. Injection of three extracted blank plasma samples during post-column infusion experiment of (A) derivatized ethinyl estradiol infusion and (B) levonorgestrel in-
fusion with a chromatogram of the ULOQ sample.
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response of unextracted samples (spiked after extraction) with
mean area of neat standard solutions at four QC levels in six dif-
ferent lots of matrices. CV (%) values for the samples were eval-
uated and matrix factor was calculated as the mean peak response
in the presence of matrix ions divided by mean peak response in
the absence of matrix ions.Overall mean IS normalized matrix factor was observed over
the range of 0.991–1.019 and 0.994–1.029 for ethinyl estradiol and
levonorgestrel, respectively.
The stability of ethinyl estradiol, levonorgestrel and respective IS
in human plasma and stock solutions was examined under different
storage conditions. Different stability experiments in plasma at two
QC levels with the values for percent changes are shown in Table 4.
Table 2
Intra-batch and inter-batch accuracy and precision.
Drug QC ID Nominal conc.a Intra-batch (n¼5) Inter-batch (n¼15)
Mean conc. founda Accuracy (%) CV (%) Mean conc. founda Accuracy (%) CV (%)
Ethinyl estradiol HQC 400 394 98.5 1.05 399 99.7 2.56
MQC1 200 210 105.0 2.09 205 102.5 2.72
MQC2 48.0 50.4 105.0 1.32 49.8 103.7 2.43
LQC 12.0 12.3 102.5 4.39 12.3 102.5 2.72
LLOQ QC 4.00 3.88 97.0 4.61 3.93 99.2 3.66
Levonorgestrel HQC 16.0 16.1 100.6 2.27 16.2 101.2 4.47
MQC1 8.00 8.53 106.6 1.78 8.35 104.4 3.89
MQC2 1.50 1.60 106.7 1.08 1.58 105.3 4.90
LQC 0.300 0.309 103.0 2.63 0.302 100.7 5.89
LLOQ QC 0.100 0.0920 92.0 8.00 0.0958 95.8 8.11
n: total number of observations; CV: coefﬁcient of variation.
a Concentration units in pg/mL and ng/mL for ethinyl estradiol and levonorgestrel, respectively.
Table 3
Absolute matrix effect, relative recovery and process efﬁciency.
Drug QC level Aa (%CV) Bb (%CV) Cc (%CV) Absolute matrix effect (%)d Relative recovery (%)e Process efﬁciency (%)f
Ethinyl estradiol HQC 2.0377 (1.77) 2.0197 (2.03) 2.0223 (1.89) 99.12 100.13 (101.52)g 99.25
MQC1 1.0075 (1.60) 1.0016 (1.59) 1.0102 (1.93) 99.41 100.86 (98.69) g 100.27
MQC2 0.2320 (2.15) 0.2344 (1.71) 0.2205 (2.42) 101.04 94.06 (95.32) g 95.04
LQC 0.0560 (3.75) 0.0571 (2.31) 0.0548 (4.01) 101.93 96.00 (97.10) g 97.86
Levonorgestrel HQC 1.9592 (2.36) 1.9465 (0.94) 1.9720 (2.62) 99.35 101.31 (96.31) g 100.65
MQC1 0.9580 (2.96) 0.9595 (0.76) 0.9879 (1.54) 100.16 102.96 (97.05) g 103.12
MQC2 0.1698 (2.05) 0.1748 (1.33) 0.1720 (2.95) 102.94 98.40 (98.73) g 101.30
LQC 0.0342 (5.04) 0.0343 (1.99) 0.0336 (3.12) 100.29 97.96 (94.78) g 98.25
CV: coefﬁcient of variation.
a Mean area ratio response of six replicate samples prepared in mobile phase (neat samples).
b Mean area ratio response of six replicate samples prepared by spiking in extracted blank plasma.
c Mean area ratio response of six replicate samples prepared by spiking before extraction.
d B A/ 100%.( ) ×
e C B/ 100%.( ) ×
f C A/ 100 Absolute matrix effect relative recovery 100%.( ) × = ( × ) ÷
g Values for IS.
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analyzed samples on different columns and mass spectrometer of
the same make and with a different analyst. The precision (%CV)
and accuracy values for different columns were found r7.95% and
99.0%–110.0%, respectively, at all four QC levels for ethinyl estra-
diol and r1.60% and 101.8%–108.0% for levonorgestrel, respec-
tively. The dilution integrity experiment was performed with the
aim to validate the dilution test to be carried out on higher analyte
concentration above the ULOQ, which may be encountered during
real subject sample analysis. The precision for dilution integrity of
1/10th dilution was 2.59% and 1.00%, while the accuracy results
were 107.0% and 110.9% for ethinyl estradiol and levonorgestrel,
respectively, which were well within the acceptance limit of 15%
for precision (%CV) and 85%–115% for accuracy.
3.3. Application to a bioequivalence study and incurred sample
reanalysis
The validated method has been successfully used to quantify
ethinyl estradiol and levonorgestrel concentrations in human
plasma samples after administration of two tablets dose of test
and reference formulations of 0.15 mg/0.03 mg levonorgestrel and
ethinyl estradiol, respectively. The study was conducted as per the
International Conference on Harmonization, E6 Good Clinical
Practice guidelines [16]. The method was sensitive enough to
monitor the ethinyl estradiol and levonorgestrel plasmaconcentration up to 72 h. In all, approximately 1800 samples in-
cluding the calibration, QC, volunteer samples and ISR samples
were run and analyzed during a period of 40 days, and the pre-
cision and accuracy were well within the acceptable limits. The
mean pharmacokinetic parameters obtained from the test and
reference formulations are presented in Table 5. The 90% CI of the
individual ratio geometric mean for test/reference formulation
was within 80%–125% for AUC0–72, AUC0-inf and Cmax under fasting
conditions as shown in Table 6. Further, there was no adverse
event during the study.
Incurred sample reanalysis study has now become an essential
part of the bioanalytical process to assess the quality of bioana-
lytical assays. It reafﬁrms the reproducibility and reliability of a
validated bioanalytical method. This was done by random selec-
tion of subject samples (10% of total samples analyzed) [17]. Out of
188 incurred samples studied, more than 98% samples showed the
change for assay reproducibility within 720% for both the drugs,
which authenticated the reproducibility of the proposed method.4. Conclusions
The bioanalytical methodology for simultaneous determination
of ethinyl estradiol and levonorgestrel described in this manu-
script can be highly useful for the therapeutic drug monitoring
both for analysis of routine samples of single dose or multiple dose
Table 5
Mean pharmacokinetic parameters following oral administration of levonorgestrel/ethinyl estradiol [2 (0.15 mg/0.03 mg)] test and reference tablets formulations in 44
healthy Indian subjects under fasting condition.
Parameter Ethinyl estradiol Levonorgestrel
Test Reference Test Reference
AUC(0–72) (h pg/mL) 17417496 17127421 146,9287121,129 134,4517115,981
AUC(0–1) (h pg/mL) 18577540 18367440 226,3877191,632 202,3307145.771
Cmax (pg/mL) 148745 144737 860274522 91,57674832
tmax (h) 1.54 (1.00–3.50) 1.74 (1.00–3.50) 1.50 (0.67–4.00) 1.25 (0.67–4.00)
Kel (1/h) 0.040170.0073 0.038970.0099 0.014570.0035 0.016170.0060
t1/2 (h) 17.973.5 18.274.02 56.6732.3 51.5723.5
Cmax: maximum plasma concentration; tmax: time point of maximum plasma concentration; t1/2: half life of drug elimination during the terminal phase; AUC0–72: area under
the plasma concentration–time curve from 0 h to 72 h; Kel: elimination rate constant.
Table 6
Comparison of treatment ratios and 90% CIs of natural log(ln)-transformed parameters for levonorgestrel/ethinyl estradiol [2 (0.15 mg/0.03 mg)] test and reference tablets












Ethinyl estradiol Cmax (pg/mL) 21.24 99.17 91.42 108.26
AUC0–72 (h pg/mL) 21.74 99.28 91.82 108.12
Levonorgestrel Cmax (ng/mL) 21.12 96.53 89.19 105.05
AUC0–72 (h ng/mL) 22.89 105.21 97.67 116.34
CV: coefﬁcient of variation.
Table 4
Stability results for ethinyl estradiol and levonorgestrel under different conditions (n¼6).
Storage condition Level Ethinyl estradiol Levonorgestrel
Mean7SD (pg/mL) Change (%) Mean7SD (ng/mL) Change (%)
Bench top stability (11 h) HQC 400.04573.961 0.0 16.28170.130 1.8
LQC 12.30470.517 2.5 0.30370.011 1.0
Dry extract stability (43 h) HQC 399.12573.215 0.2 16.40570.647 2.5
LQC 12.18970.297 1.6 0.29170.006 3.0
Wet extract stability (43 h) HQC 401.95879.156 0.5 16.00570.472 0.0
LQC 12.39270.453 3.3 0.30370.008 1.0
Freeze–thaw stability (5 cycles, 20 °C) HQC 402.12473.712 0.5 16.39670.295 2.5
LQC 11.70470.195 2.5 0.29570.004 1.7
Freeze–thaw stability (5 cycles, 70 °C) HQC 399.25175.224 0.2 16.50270.361 3.1
LQC 12.20070.466 1.7 0.29470.009 2.0
Long-term stability in plasma (215 days, 70 °C) HQC 416.75071.523 4.2 16.40370.148 2.5
LQC 12.89870.327 7.5 0.30670.0084 2.6
Stability of drug in blood (2 h)a HQC NA 1.7 NA 1.9
LQC NA 0.7 NA 4.3
SD: standard deviation; n: number of replicates at each level; NA: not applicable.
a Change (%) on basis of peak area ratio of comparison and stability samples.
Change %
Mean stability samples Mean comparison samples
Mean comparison samples
100%( ) = – ×
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valence studies with precision, accuracy and high throughput.
Date processing was done using the LIMS software which gave the
highest data integrity during the method validation and sample
analysis. The method involved a sample preparation by protein
precipitation, LLE and derivatization followed by LLE. The analy-
tical separation was followed by gradient chromatographic se-
paration in 9.0 min. The validated method was found to be spe-
ciﬁc, sensitive, accurate and precise. The established LLOQ wassufﬁciently low to conduct a pharmacokinetic study with 0.03 mg
test formulation of ethinyl estradiol and 0.075 mg of levonorges-
trel in healthy human volunteers.Acknowledgments
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